Neoplasms

All Conditions

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Carcinoma

Nasopharyngeal Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Capecitabine

Carboplatin

Docetaxel

Fluorouracil

Cisplatin

Arm 1: EBV DNA \<4000 copies/mL AND T3N0-2 or T4N0 (TNM AJCC/UICC 8th edition)

Arm 2: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA undetectable after 2-3 cycles of induction chemotherapy (IC)

Arm 3: EBV DNA ≥4000 copies/mL OR N3 OR T4N+ (TNM AJCC/UICC 8th edition) AND EBV DNA detectable after 2-3 cycles of IC

Group 1: Recurrent/metastatic NPC, EBV DNA \<4000 copies/mL

Group 2: Recurrent/metastatic NPC, EBV DNA ≥4000 copies/mL

Concurrent chemoradiotherapy (CCRT) using cisplatin (100 mg/m2 IV) or carboplatin (AUC 5 IV) with radiotherapy +/- adjuvant chemotherapy (AC) with capecitabine (physician's choice of 650 mg/m2 bid or 1000 mg/m2 bid oral, d1-21, q3w)

Arm 1

IC using cisplatin (80 mg/m2 IV) or carboplatin (AUC 3-5 IV) in combination with gemcitabine (1000 mg/m2 d1,8) or 5-fluorouracil (1000 mg/m2 bolus IV d1-4) or docetaxel (75 mg/m2 IV), and CCRT

Arm 2

CCRT + metronomic capecitabine (650 mg/m2 bid oral, d1-21, q3w)

Arm 3

Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) and consolidative RT to the nasopharynx and neck (if good response to chemotherapy) +/- metastasis-directed therapy (surgery, radiofrequency ablation or RT) +/- immune checkpoint blockade (ICB) or capecitabine

Group 1

Combination chemotherapy (using cisplatin or carboplatin with gemcitabine, 5-fluorouracil or docetaxel) with or without ICB +/- maintenance ICB or capecitabine

Group 2

Melvin Lee Kiang Chua, MBBS, FRCR, PhD, FAMS

This is a prospective platform study that will investigate the outcomes of patients with locoregionally-advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) who are assigned to treatment arms of different chemotherapy sequencing and intensity based on their pre- and on-treatment plasma EBV DNA results.

The primary objectives of this platform are: (1) to prospectively validate the prognostic potential of an EBV DNA-based risk-stratification strategy of patients with LA- and RM-NPC; and (2) to test if treatment individualization strategies based on pre- and on-treatment plasma EBV DNA will improve survival outcomes. Primary study end-point is 2-year disease-free survival (DFS).

Archival tissue, fresh tumour biopsy tissue, saliva and peripheral blood samples will be obtained for this study

Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study

Blood samples will be collected at up to 7 timepoints - baseline, mid/post IC, mid CCRT, 1-2 weeks post-RT, 3 months post-RT/mid-adjuvant chemotherapy, at point of recurrence and post immune checkpoint blockade treatment (for recurrence, if any); fresh biopsy samples will be collected at baseline and at point of recurrence, if amenable for biopsy. Saliva samples will be collected at baseline and at point of recurrence.

National Cancer Centre, Singapore

Digestive System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Educational small group session with free FOBT kit

Educational small group session with no FOBT kit

Educational small group session, exercise

Annette E Maxwell, Dr.P.H.

Develop and evaluate in a randomized trial an educational small group intervention to increase colorectal cancer screening among Filipino Americans.

The purpose of this research study is to increase colorectal cancer (CRC) screening among older Filipino Americans, specifically the use of fecal occult blood tests (FOBTs). We will design a culturally specific intervention, an educational small group discussion with a Filipino health professional. The effect of the intervention will be tested with 620 Filipino Americans. Subjects will be recruited at community-based organizations and churches and invited to join a 1 1/2 hour discussion of health issues with their partner and some of their friends. A third of the subjects will discuss exercise (control group), another third will discuss CRC and receive an FOBT kit, and the remaining third will discuss CRC and will not receive an FOBT kit. Three months after the group session, subjects in the CRC (intervention) groups will receive a letter reminding them to get screened. All subjects will be interviewed before and 6 months after the group sessions to assess CRC screening levels in the three groups. Self-reported CRC screening will be verified by a review of their medical records.

Increasing Colorectal Cancer Screening Among Filipino Americans

American Cancer Society, Inc.

Jonsson Comprehensive Cancer Center

Symptoms and General Pathology

Blood and Lymph Conditions

Syndrome

Leukemia

Preleukemia

Myelodysplastic Syndromes

Hematologic Diseases

Acute Graft Versus Host Disease

Antirheumatic Agents

Tacrolimus

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Complement System Proteins

Complement Factor H

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Calcineurin Inhibitors

Enzyme Inhibitors

Experimental: Total marrow irradiation 1.5 Gray (Gy) twice a daily on days -3 and -2

Arm1

All patients will receive the following standard conditioning regimen:

Fludarabine 30 mg/m2 IVPB daily from Day -6 (6 days before stem cell infusion) through Day -2

IV cyclophosphamide 14.5 mg/kg intravenously prior to transplant on Days -6 and -5.

Tacrolimus IV initially in doses of 0.15 mg/kg/day for 3 days, followed by conversion to oral therapy (0.15 mg/kg twice daily)

Cyclophosphamide on days 3 and 4 after transplant at a dose of 50mg/kg per day

Rondelli Damiano, MD

Marisol Vega, MS

Pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4 along with tacrolimus and mycophenolate mofetil

This is a single arm phase II clinical trial. Patients will receive a standard conditioning regimen with fludarabine, cyclophosphamide and total body irradiation (Flu/Cy/TBI) prior to haploidentical hematopoietic stem cell transplant (HSCT). In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI) at a dose of 6Gy. Graft-versus-host disease prophylaxis will include cyclophosphamide 50 mg/kg on Day +3 and 4 along with tacrolimus and mycophenolate mofetil.

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

BMT-06: Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Cyclophosphamide and Post-Transplant Cyclophosphamide Conditioning for Partially HLA Mismatched (Haploidentical) Allogeneic Transplantation in Patients With Acute Leukemia and Myelodysplastic Syndrome (MDS)

To evaluate the number of patients with acute leukemia or MDS that are GVHD free

To evaluate the number of patients with acute leukemia or MDS that are relapse free survival

Evaluate the incidence of greater than or equal to grade 4 non-hematologic toxicities

Rates of incidence of full donor chimerism at day 30

The rate of Grade II-IV and III-IV acute GVHD and limited/extensive chronic GVHD

The rate of progression at 1 year post transplant

The rate of relapse at 1 year post transplant

The rate of non-morality (NRM) at 1 year post transplant

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study	NCT05517135	Nasopharyngeal ...	Arm 1 Arm 2 Arm 3 Group 1 Group 2	21 Years - 99 Years	National Cancer Centre, Singapore
Treatment Individualisation by EBV Stratification in Nasopharyngeal Carcinoma: a Prospective Observational Study	NCT05517135	Nasopharyngeal ...	Arm 1 Arm 2 Arm 3 Group 1 Group 2	21 Years - 99 Years	National Cancer Centre, Singapore
Increasing Colorectal Cancer Screening Among Filipino Americans	NCT00742729	Colorectal Canc...	Arm 1 Arm 2 Arm 3	50 Years - 70 Years	Jonsson Comprehensive Cancer Center
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)	NCT04187105	Acute Leukemia MDS	Arm1 Arm1 Arm1 Arm 1 Arm1 Arm1 Arm1	18 Years - 75 Years	University of Illinois at Chicago
Increasing Colorectal Cancer Screening Among Filipino Americans	NCT00742729	Colorectal Canc...	Arm 1 Arm 2 Arm 3	50 Years - 70 Years	Jonsson Comprehensive Cancer Center
Increasing Colorectal Cancer Screening Among Filipino Americans	NCT00742729	Colorectal Canc...	Arm 1 Arm 2 Arm 3	50 Years - 70 Years	Jonsson Comprehensive Cancer Center
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)	NCT04187105	Acute Leukemia MDS	Arm1 Arm1 Arm1 Arm 1 Arm1 Arm1 Arm1	18 Years - 75 Years	University of Illinois at Chicago

Spots Global Cancer Trial Database for arm 1

Every month we try and update this database with for arm 1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for arm 1

Every month we try and update this database with for arm 1 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for arm 1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.